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Abstract
Heat shock protein 90 (Hsp90) is a protein chaperone that is upregulated and released from
pancreatic β cells under pro-inflammatory conditions. We hypothesized that serum Hsp90
may have utility as a biomarker of type 1 diabetes risk and exhibit elevations before the
onset of clinically significant hyperglycemia. To this end, total levels of the alpha cytoplasmic
isoform of Hsp90 were assayed in autoantibody-positive progressors to type 1 diabetes
using banked serum samples from the TrialNet Pathway to Prevention Cohort that had been
collected 12 months prior to diabetes onset, with comparison to age, sex, and BMI-category
matched autoantibody-positive nonprogressors and healthy controls. Hsp90 levels were
higher in autoantibody-positive progressors and nonprogressors� 18 years of age com-
pared to matched healthy controls. However, Hsp90 levels were not different between pro-
gressors and nonprogressors in any age group. Hsp90 was positively correlated with age in
control subjects, but this correlation was absent in autoantibody positive individuals. In
aggregate these data indicate that elevated Hsp90 levels are present in youth with β cell
autoimmunity, but are not able to distinguish youth or adult type 1 diabetes progressors from
nonprogressors in samples collected 12 months prior to diabetes development.
Introduction
Type 1 diabetes (T1D) has been defined classically as a T cell-mediated autoimmune disease in
which insulin-producing β cells are targeted for destruction by the host immune system. At
present, a lack of reliable biomarkers remains a major obstacle in both the identification of
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individuals at-risk of developing T1D and in the implementation of disease modifying thera-
pies [1]. Recent data have highlighted a role for β cell stress pathways such as endoplasmic
reticulum stress and oxidative stress that may synergize with the immune system to accelerate
T1D progression [2, 3]. Activation of these pathways is thought to precede the development of
clinically detectable hyperglycemia [4], thus raising the possibility that biomarkers of β cell
health may have utility in disease prediction and treatment paradigms.
Heat shock protein 90 (Hsp90) is a highly-conserved member of the heat-shock family of
molecular chaperone proteins. Intracellularly, these chaperones assist a wide variety of protein
clients in the acquisition of active conformations using energy derived from ATP binding and
hydrolysis [5]. Islet Hsp90 levels were shown recently to be elevated in NOD mice prior to the
onset of hyperglycemia [6]. In other cell types, intracellular Hsp90 expression and Hsp90
release are increased in response to reactive oxygen species and other environmental stressors
such as hypoxia and irradiation [7]. Consistent with these findings, cadaveric human islets and
pancreatic β cell lines released increased levels of Hsp90 in response to pro-inflammatory cyto-
kine treatment [8, 9]. Moreover, pediatric subjects with recent-onset T1D demonstrated ele-
vated serum levels of the alpha cytoplasmic isoform of Hsp90 compared to age and sex-
matched controls [6], while elevated levels of circulating IgG1 and IgG3 class-switched anti-
Hsp90 autoantibodies have been identified in individuals with T1D [10].
Taken together, these data suggest that extracellular and potentially β cell-derived Hsp90
may be indicative of ongoing β cell stress and islet inflammation during the evolution of T1D.
We therefore hypothesized elevations in serum Hsp90 levels may be present prior to the onset
of clinical symptoms of diabetes and serve to predict T1D development. To this end, serum
Hsp90 levels were assayed in samples from the TrialNet Pathway to Prevention (PTP) cohort,
which is a longitudinal study of at-risk, autoantibody-positive relatives of individuals with
T1D who are prospectively monitored for the development of dysglycemia and diabetes.
Serum Hsp90 was measured in individuals who progressed to T1D in samples collected
approximately 12 months prior to the onset of clinical disease, and levels were compared to
age-, sex-, and BMI-matched healthy controls and autoantibody positive nonprogressors who
remained diabetes-free.
Methods
Biobanked Serum Samples
TrialNet is an ongoing clinical trial with centers in the United States, Canada, United King-
dom, Germany, Italy, Australia, and New Zealand. The TrialNet Pathway to Prevention (PTP)
study (TN01; clinical trial reg. no. NCT00097292, clinicaltrials.gov) longitudinally monitors
autoantibody positive first-, second-, and third-degree blood relatives of persons with T1D for
changes in autoantibody status, dysglycemia, and progression to T1D [11]. Serum is regularly
collected and banked at the time of oral glucose tolerance testing. For this study, we analyzed
stored serum samples collected from 60 autoantibody-positive TrialNet PTP study participants
collected approximately 12 months before the development of type 1 diabetes. Diabetes was
diagnosed according to criteria established by the American Diabetes Association [12]. To
approximate prepubertal, peripubertal, and postpubertal age groups, equal numbers of pro-
gressors were chosen from three age ranges (< 10, 10–18, and> 18 years of age). In addition,
banked serum samples were obtained from autoantibody-positive PTP participants who did
not progress to T1D with the same type and length of monitoring. These autoantibody-positive
nonprogressors were chosen to match progressors based on age, sex, and BMI/BMI z scores.
Banked pediatric serum samples from age, gender, and BMI z-score healthy controls were
obtained locally at Indiana University from ambulatory dental and eye clinics. Control
Hsp90 as a biomarker of type 1 diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0208456 January 10, 2019 2 / 10
Ball Foundation, and the Holiday Management
Foundation (to C.E-M. and R.G.M.). RAO is
supported by a Diabetes UK Harry Keen Fellowship
(16/0005529). This work utilized core services
provided by the Diabetes Research Center grant
P30 DK097512 (to Indiana University School of
Medicine). Our analysis involved material and data
provided by the Type 1 Diabetes TrialNet Study
Group. The Type 1 Diabetes TrialNet Study Group
is a clinical trial network funded by the National
Institutes of Health (NIH) through the National
Institute of Diabetes and Digestive and Kidney
Diseases, the National Institute of Allergy and
Infectious Diseases, and the Eunice Kennedy
Shriver National Institute of Child Health and
Human Development, through cooperative
agreements U01 DK061010, U01 DK061034, U01
DK061042, U01 DK061058, U01 DK085465, U01
DK085453, U01 DK085461, U01 DK085466, U01
DK085499, U01 DK085504, U01 DK085509, U01
DK103180, U01 DK103153, U01 DK085476, U01
DK103266, U01 DK103282, U01 DK106984, U01
DK106994, U01 DK107013, U01 DK107014, UC4
DK106993, and the JDRF. The funders had no role
in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
pediatric subjects did not take any chronic prescription medications, had no chronic health
diagnoses or family history of diabetes, and had no acute febrile illness within two weeks pre-
ceding sampling. Banked adult serum samples were also obtained at Indiana University from
age, gender, and BMI-matched healthy controls who were recruited on the basis of a normal
response during an oral glucose tolerance test. Exclusion criteria for adult controls included a
history of any type of diabetes, current pregnancy, weight fluctuation in the preceding 6
months, current or past tobacco use, acute or chronic illness, pulmonary disease, or use of anti-
depressants, metformin, or thiazolidinediones.
TrialNet protocols were approved by local Institutional Review Boards. Collections at Indi-
ana University were approved by the Indiana University Institutional Review Board. Written
informed consent or parental consent and child assent were obtained from all participants
before any research participation in accordance with the ethical guidelines of each institution.
TrialNet consents explicitly allowed use of stored samples in ancillary studies such as the cur-
rent project.
Hsp90 ELISA and T1D Autoantibody Assays
Total serum levels of the alpha cytoplasmic isoform of Hsp90 were measured by ELISA (Enzo
Life Sciences). This assay detected Hsp90 levels in the range of 62.5–4000 pg/mL, with a
reported sensitivity of 50 pg/mL and no cross-reactivity with the beta cytoplasmic isoform of
Hsp90, Grp94, Hsp60, or Hsp70. Autoantibodies to GAD65 or GAD65H, microinsulin anti-
bodies (mIAAs), islet cell antibodies (ICAs), or IA-2H were measured according to methods
outlined by the Diabetes Antibody Standardization Program as described previously [11].
Given that TrialNet recently replaced GAD65 and ICA512 with GAD65H and IA-2H assays,
individuals with positive results for either assay were considered positive for GAD or ICA
autoantibodies.
Statistics
Because several sets of data in our analysis were not normally distributed according to D’Agos-
tino-Pearson omnibus normality tests, continuous data were graphed as medians with inter-
quartile ranges (IQRs) and analyzed using non-parametric statistical tests. Non-parametric tests
are less sensitive to outlier points and are more suitable for data derived from non-normal dis-
tributions [13]. For comparisons between two groups, statistical significance was determined
using a two-tailed Mann-Whitney test. To determine statistical significance among three
groups, the Kruskal-Wallis test was used with Dunn’s test to correct for multiple comparisons.
Receiver operating characteristic (ROC) analysis was performed to determine area under the
curve (AUC) using Stata 14 (Statacorp LP, Texas, USA). Spearman correlations were used to
analyze relationships between serum Hsp90 levels and demographic variables. Categorical vari-
ables were compared among groups by Pearson’s chi-square tests. P-values of< 0.05 were con-
sidered statistically significant. Statistics were calculated using GraphPad Prism 7.0c (GraphPad
Software). The complete dataset is included in the Supporting Information.
Results
Characteristics for the 60 control subjects, 60 autoantibody-positive TrialNet nonprogressors,
and 60 autoantibody-positive TrialNet progressors are shown in Table 1. No differences in
age, sex, or BMI z-scores were observed between the groups. Within the progressor and non-
progressor PTP groups, 56 subjects tested positive for 0–1 autoantibodies, while 64 subjects
tested positive for two or more autoantibodies. As expected, a higher percentage of progressors
were positive for two or more autoantibodies compared to the nonprogressors (P< 0.0001).
Hsp90 as a biomarker of type 1 diabetes
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Median serum Hsp90 values by age category for autoantibody-negative control subjects
were as follows: 11.8 ng/mL (IQR 8.2, 15.4) in subjects < 10 years of age, 8.4 ng/mL (IQR 7.3,
11.1) in subjects 10–18 years of age, and 17.9 ng/mL (IQR 11.1, 22.7) in subjects > 18 years of
age. In the autoantibody positive non-progressor group, median serum Hsp90 values were
21.3 ng/mL (IQR 15.2, 27.4) in subjects < 10 years of age, 20.9 ng/mL (IQR 13.6, 26.1) in sub-
jects 10–18 years of age, and 19.6 ng/mL (IQR 14.9, 28.1) in subjects> 18 years of age. For pro-
gressors, median serum Hsp90 values were 22.0 ng/mL (IQR 17.2, 33.6) in subjects < 10 years
of age, 19.4 ng/mL (IQR 10.5, 26.2) in subjects 10–18 years of age, and 16.5 ng/mL (IQR 10.2,
24.3) in subjects > 18 years of age.
Comparison between groups showed that serum Hsp90 levels were significantly higher in
autoantibody-positive nonprogressors and progressors compared to control subjects in
persons < 10 years of age (P = 0.0017 and P = 0.0004, respectively) and 10–18 years of age
(P< 0.0001, P = 0.0001, respectively). In these age groups, however, no differences in HSP90
levels were detected between autoantibody-positive nonprogressor and progressor subjects
(Fig 1A and 1B). Analysis of subjects > 18 years of age revealed no differences in Hsp90 levels
among the three groups (P = 0.273) (Fig 1C).
ROC analysis was used to examine the discriminative ability of serum Hsp90 levels in dis-
tinguishing controls from autoantibody-positive subjects� 18 years of age. An area under the
curve (AUC) of 1 in ROC analysis represents perfect discrimination, while an AUC of>0.8 is
considered a clinically useful test [14]. The area under to curve (AUC) for Hsp90 was calcu-
lated to be 0.84 [95% confidence interval (CI): 0.77–0.91; P< 0.0001] (Fig 2), confirming the
ability of Hsp90 to distinguish youth with autoimmunity from a healthy control population.
Table 1. Baseline Characteristics of Study Participants.
Variable: median (IQR) Aab Negative
(n = 60)
Non-Progressors (n = 60) Progressors (n = 60) P value
Age (years) 12.0 (8.0, 25.8) 12.0 (7.3, 25.0) 11.6 (7.8, 26.5) ns
Male sex (%) 48.3 48.3 48.3 ns
BMI—for—age (z-score) 0.76 (-0.12, 1.73) 0.76 (-0.01, 1.28) 0.68 (-0.13, 1.42) ns
Multiple Aab positive (%) 0 40.0 66.7 < 0.0001
https://doi.org/10.1371/journal.pone.0208456.t001
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Fig 1. Serum Hsp90 values in TrialNet PTP study participants. Scatterplots of serum Hsp90 values for subjects< 10 years of age; n = 20 in
each group (A), 10–18 years of age; n = 20 in each group (B), and> 18 years of age; n = 20 in each group (C). Kruskal-Wallis tests demonstrated
significant differences between groups for subjects< 10 years of age (P = 0.0001) and 10–18 years of age (P< 0.0001), but not for subjects> 18
years of age. Dunn’s multiple comparisons tests revealed significant differences between autoantibody-positive nonprogressors and progressors
compared to autoantibody-negative controls in subjects< 10 years of age (P = 0.0017 and P = 0.0004, respectively) and 10–18 years of age
(P< 0.0001, P = 0.0001, respectively). No differences were observed between nonprogressor and progressor subjects for either age group.
��P< 0.01, ���P< 0.001, ����P< 0.0001. NP: nonprogressor, P: progressor.
https://doi.org/10.1371/journal.pone.0208456.g001
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To determine whether serum Hsp90 levels were different in those with greater numbers of
detectable islet autoantibodies, serum Hsp90 levels were assessed relative to autoantibody sta-
tus. No differences in serum Hsp90 levels were detected between progressor and nonprogres-
sor subjects positive for 0–1 autoantibody compared to those who were positive for two or
more autoantibodies (P = 0.57) (Fig 3).
Because we found that Hsp90 levels were elevated in pre-pubertal and pubertal subjects (Fig
1), we also examined correlations between serum Hsp90 levels and age. In control subjects,
serum Hsp90 levels were significantly higher with age (rs = 0.35, P = 0.007) (Fig 4A). Con-
versely, serum Hsp90 levels exhibited a weak inverse correlation with age in autoantibody-
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Fig 2. ROC curve analysis of serum Hsp90 levels to predict autoantibody-positivity in subjects� 18 years of age.
ROC analysis was performed to determine the utility of serum Hsp90 levels as a predictor of autoantibody-positivity in
subjects� 18 years of age. (AUC: 0.84; 95% CI: 0.77–0.91; P< 0.0001).
https://doi.org/10.1371/journal.pone.0208456.g002
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Fig 3. Relationship of serum Hsp90 levels with islet autoimmunity. Scatterplot comparing serum Hsp90 levels in
subjects testing positive for 0–1 (n = 56) and two or more (n = 64) islet autoantibodies (AutoAb). No difference was
observed by Mann-Whitney test (P = 0.57).
https://doi.org/10.1371/journal.pone.0208456.g003
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positive subjects (n = 120) (rs = -0.18, P = 0.06) (Fig 4B). We analyzed correlations with age
separately for the nonprogressors (Fig 4C) and progressors (Fig 4D). There was a significant
negative inverse correlation with age in the progressors to type 1 diabetes (rs = -0.275, P =
0.033), whereas no significant relationship between serum Hsp90 levels and age was observed
in the nonprogressors (rs = -0.045, P = 0.734). No significant correlations were found between
serum Hsp90 levels and sex or BMI/BMI z-scores (data not shown).
Discussion
Hsp90 is an attractive biomarker of T1D risk based on a growing body of evidence implicating
islet β cell endoplasmic reticulum (ER) stress in T1D pathogenesis. Protein markers of ER
stress are upregulated in islets of humans with T1D [15]. In addition, ER stress is known to
precede the development of T1D in NOD mice [16], while mitigation of ER stress with
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Fig 4. Correlations of serum Hsp90 levels with age. Spearman correlation coefficients were generated to test correlation of serum Hsp90 levels
with age in n = 60 autoantibody-negative (A) and n = 120 autoantibody-positive (B) subjects and then separately for the nonprogressors
(n = 60) (C) and progressors (n = 60) (D). A significant positive correlation between serum Hsp90 levels and age was observed in autoantibody-
negative subjects (rs = 0.35, P = 0.007), while serum Hsp90 levels exhibited a weak trend toward decreasing with age in autoantibody-positive
subjects (rs = -0.18, P = 0.06). No significant relationship with age was observed in the nonprogressor group (rs = -0.045, P = 0.734). However,
there was a significant negative inverse correlation with age in the progressors to type 1 diabetes (rs = -0.275, P = 0.033).
https://doi.org/10.1371/journal.pone.0208456.g004
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chemical chaperones prevented the development of T1D in NOD mice [17]. Pro-inflammatory
cytokines are released locally within the pancreas by activated macrophages, natural killer
cells, and T cells during the course of insulitis [9]. Ex vivo treatment of human cadaveric islet
cells and β cell lines with pro-inflammatory cytokines has been shown also to induce ER stress
[18]. Consistent with this, we previously found that pro-inflammatory cytokines induced
release of Hsp90 from β cells [8] and that HSP90 protein expression is elevated in islets from
pre-diabetic NOD mice at a time when ER stress is known to be present. Moreover, we have
shown that serum Hsp90 levels were elevated in pediatric subjects at the time of T1D diagnosis
[6]. Whether Hsp90 levels are elevated prior to a clinical diagnosis of Stage 3 T1D, therefore
serving as a biomarker of T1D risk, has not been tested.
To this end, we measured serum levels of Hsp90 in samples obtained from T1D progressors
and nonprogressors followed in the TrialNet Pathway to Prevention Cohort. We tested a time-
point 12 months before diabetes onset, because natural history studies have identified this as a
period of accelerated loss of C-peptide and rising glycemia [19–21]. We found that serum
Hsp90 levels were higher in autoantibody-positive subjects < 10 years of age and 10–18 years
of age compared to healthy control subjects (Fig 1A and 1B). However, Hsp90 levels were not
different between autoantibody positive T1D progressors and nonprogressors who were fol-
lowed for an equivalent length of time (Fig 1A–1C). In addition, levels of Hsp90 were not
increased in progressors or nonprogressors over age 18 compared to matched controls (Fig
1C).
Hsp90 is expressed in a number of tissues, including immune cells. Indeed, studies have
demonstrated elevations in serum Hsp90 levels in a variety of other autoimmune and inflam-
matory conditions. In a cohort of individuals with bullous pemphigoid, skin as well as periph-
eral blood mononuclear cell (PBMC) levels of Hsp90 were elevated relative to controls [22].
PBMC Hsp90 levels were also elevated in systemic lupus erythematosus, and levels correlated
with increased levels of circulating IgG autoantibodies to Hsp90 [23]. Thus, elevations in
serum Hsp90 levels may reflect more generalized states of inflammation as might be expected
in individuals with β cell autoimmunity.
Analyses were performed to explore whether elevations in Hsp90 were related to key demo-
graphic and clinical variables. We did not detect a difference in Hsp90 levels by number of
autoantibodies in the progressor and nonprogressor groups (Fig 3). This could indicate that
Hsp90 becomes elevated early during autoimmunity and remains chronically elevated without
significant fluctuation with the intensity of autoimmunity. Future longitudinal analysis would
be needed to fully test this possibility. Interestingly, Hsp90 levels exhibited a decreasing trend
with age in autoantibody-positive subjects and a significant decreasing trend with age in the
progressors to type 1 diabetes (Fig 4B and 4D). These results were similar to our previous
study examining correlations between age and serum Hsp90 level in children aged 4–15 years
with new-onset T1D [6] and could be indicative of the aggressive β cell autoimmunity typically
experienced by younger individuals [24, 25]. Related to this, levels of HSP90 were not different
in older progressors >18 years compared to matched controls (Fig 1C). Notably, we observed
increasing serum Hsp90 levels with age in control subjects (Fig 4A), and these age-related ele-
vations may have obscured any differences in serum Hsp90 levels that were associated with
autoantibody status in this older age group. Associations between aging and inflammation are
well-established, and increased expression of inflammatory markers has been referred to as
“inflammaging”, a process thought to contribute to accelerated aging and decreased lifespan in
older adults [26]. Interestingly, Hsp90 inhibitors were shown recently to have therapeutic effi-
cacy to extend lifespan, acting as a senolytic agent in rodents [27]. Therefore, the possibility
remains that elevated baseline levels of serum Hsp90 in older individuals reveal the increased
inflammation associated with aging, while the absence of these age-related elevations make
Hsp90 as a biomarker of type 1 diabetes
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Hsp90 a more suitable biomarker to detect pathological inflammatory processes in younger
individuals.
In summary, this study was the first to examine whether elevations in serum Hsp90 levels
precede T1D development. Our results indicate that elevated serum levels of Hsp90 may be
associated with β cell autoimmunity in pediatric patients. However, differences in Hsp90 levels
were not able to predict whether or not an autoantibody-positive individual will develop T1D
within a 12-month timeframe.
Supporting information
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